Brentuximab vedotin 维布妥昔单抗；本妥昔单抗|cas:914088-09-8|西域试剂

Brentuximab vedotin 维布妥昔单抗；本妥昔单抗,98.00%

产品编号：Bellancom-P99107| CAS NO：914088-09-8

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99107		￥5000.00	杭州北京（现货）
Bellancom-P99107		￥12500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Brentuximab vedotin 维布妥昔单抗；本妥昔单抗

产品介绍

Brentuximab vedotin (cAC10-vcMMAE) 是一种抗体-活性分子偶联物 (ADC)，由抗 CD30 抗体和 Monomethyl auristatin E (MMAE) 组成。Brentuximab vedotin 抑制 CD30 阳性细胞，其 IC₅₀ 值为 2.5 ng/mL。Brentuximab vedotin 可用于复发难治性霍奇金淋巴瘤的研究。

生物活性

Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC₅₀ of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.

体外研究

Brentuximab vedotin (cAC10-vcMMAE) (1 μg/mL; 96 h) shows cytotoxicity to CD30⁺ in Karpas 299 cells.
Brentuximab vedotin (CAC10-VCMMAE) (1 μg/mL; 12, 24 and 48 h) selectively induces growth arrest in G2/M phase then lead to apoptotic cell death.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line:	Karpas 299 cells
Concentration:	1 μg/mL
Incubation Time:	96 h
Result:	Showed cytotoxicity to CD30⁺ Karpas 299 cells with an IC₅₀ value of 2.5 ng/mL.

Cell Cycle Analysis

Cell Line:	L540 cells
Concentration:	1 μg/mL
Incubation Time:	12, 24, and 48 h
Result:	Selectively induced growth arrest in G2/M phase to apoptotic cell death.

体内研究
(In Vivo)

Brentuximab vedotin (cAC10-vcMMAE) (10-120 mg/kg; i.p. for 3 weeks) the maximum tolerated dose (MTD) is between 30 and 40 mg/kg.
Brentuximab vedotin (cAC10-vcMMAE) (0.3, 1 mg/kg; flanks injection; every 4 days for a total of 4 doses 1 mg/kg) induces tumor CD30 regression.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice
Dosage:	10 to 120 mg/kg
Administration:	Intravenous injection; 10 to 120 mg/kg; for 3 weeks
Result:	Showed an maximum tolerated dose between 30 and 40 mg/kg.

Animal Model:	SCID mice
Dosage:	0.3 and 1 mg/kg
Administration:	Flanks injection; 1 mg/kg every 4 days for a total of 4 doses; 0.3 mg/kg every 4 days for a total of 4 doses
Result:	Induced complete and durable tumor regression, but 0.3 mg/kg provided lower therapy than 1 mg/kg dose.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice
Dosage:	10 to 120 mg/kg
Administration:	Intravenous injection; 10 to 120 mg/kg; for 3 weeks
Result:	Showed an maximum tolerated dose between 30 and 40 mg/kg.

Animal Model:	SCID mice
Dosage:	0.3 and 1 mg/kg
Administration:	Flanks injection; 1 mg/kg every 4 days for a total of 4 doses; 0.3 mg/kg every 4 days for a total of 4 doses
Result:	Induced complete and durable tumor regression, but 0.3 mg/kg provided lower therapy than 1 mg/kg dose.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice
Dosage:	10 to 120 mg/kg
Administration:	Intravenous injection; 10 to 120 mg/kg; for 3 weeks
Result:	Showed an maximum tolerated dose between 30 and 40 mg/kg.

Animal Model:	SCID mice
Dosage:	0.3 and 1 mg/kg
Administration:	Flanks injection; 1 mg/kg every 4 days for a total of 4 doses; 0.3 mg/kg every 4 days for a total of 4 doses
Result:	Induced complete and durable tumor regression, but 0.3 mg/kg provided lower therapy than 1 mg/kg dose.